The Association Between Human Microbiome and Vitamin D in Chronic Urticaria

Overview

A double-blind study to evaluate the role of human microbiome and vitamin D in the development of urticaria.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: March 31, 2025

Detailed Description

Urticaria is a chronic allergic inflammatory disorder. Genetic and environmental factors, such as exposure to allergens and microbes, have a detrimental role in the development of chronic urticaria. Vitamin D also has an important role in urticaria. Lower sera vitamin D level was observed in patients that developed urticaria. Vitamin D binding protein (DBP) bound to vitamin D and regulated its metabolites in the circulation. Moreover, vitamin D receptors (VDR) have been identified on nearly all cells of the immune system. It may contribute to maintenance of intestinal barrier function by preventing increased intestinal permeability, dysbiosis, inflammation, and a lack of immune tolerance in the gut. The investigators plan to design a double-blind trial to evaluate the role of human microbiome and vitamin D in the development of urticaria. We will enroll children with chronic urticaria (CU) and age and gender matched healthy children,and collected their venous blood and microbiome samples of nasal and anal swab. Then, CU subjects will be given vitamin D or placebo for 6 months in a randomized, double-blind way. After six months of follow-up, their blood, nasal cavity, and intestinal bacterial samples were taken. All microbial analysis, allergen detection, vitamin D concentration, VDR, DBP genotype will be analyzed by the core laboratory and bioinformatics center of CMUH. The investigators believe this study can answer the cause-effect relationships of microbiota and vitamin D in the development of CU, and design a microbiota-related preventive and treatment strategy.

Interventions

  • Other: Vitamin D
    • Vitamin D (2000IU/day) for 6 months
  • Other: Placebo
    • Placebo

Arms, Groups and Cohorts

  • Experimental: Treatment group
    • Vitamin D (2000IU/day) for 6 months
  • Placebo Comparator: Control group
    • placebo

Clinical Trial Outcome Measures

Primary Measures

  • Levels of vitamin D
    • Time Frame: Month 0
    • Vitamin D will be measured in a blood sample by ELISA to determine baseline status.
  • Levels of vitamin D
    • Time Frame: Month 6
    • Vitamin D will be measured in a blood sample to follow the change from baseline in vitamin D level at month 6.
  • Single nucleotide polymorphism of vitamin D receptor and vitamin D binding protein.
    • Time Frame: Month 0
    • Single nucleotide polymorphism (SNP) genotyping will be performed in a blood sample by using TaqMan SNP genotyping assays.
  • Microbiome Microbiome
    • Time Frame: Month 0
    • Nasal and anal swabs will be used to detect respiratory and intestinal microbiome by using 16S rRNA sequencing to determine baseline status.
  • Microbiome Microbiome
    • Time Frame: Month 6
    • Nasal and anal swabs will be used to detect respiratory and intestinal microbiome by using 16S rRNA sequencing,and to follow the change from baseline in microbiome at month 6.
  • Total IgE
    • Time Frame: Month 0
    • Plasma total IgE concentration will be measured by microparticle immunoassay (IMx analyzer, Abbott Laboratories, Abbott Park, IL) and ELISA to determine baseline status.
  • Total IgE
    • Time Frame: Month 6
    • Plasma total IgE concentration will be measured by microparticle immunoassay (IMx analyzer, Abbott Laboratories, Abbott Park, IL) and ELISA to follow the change from baseline in total IgE at month 6.
  • Allergen-specific IgE
    • Time Frame: Month 0
    • Plasma allergen-specific IgE will be measured by BioIC ®.

Secondary Measures

  • Quality of Life Assessment
    • Time Frame: Month 0 to Month 6
    • Patients will rate their CU symptoms and the impact of their CU on various aspects of their lives. Each question is scored from 0 (not at all) to 3 (very much). Overall score, on scale of 0 to 57.
  • The Urticaria Activity Score 7 (UAS7)
    • Time Frame: Month 0 to Month 6
    • The Urticaria Activity Score 7 measures number the weekly average of hives and pruritus measured twice a day. It scores from 0 to 42.

Participating in This Clinical Trial

Inclusion Criteria

1. Experimental group: patients with chronic spontaneous urticaria under the age of 18 . 2. Control group: healthy children under the age of 18 (eg, healthy siblings of sick children). Exclusion Criteria:

1. Recruit patients who have used antibiotics, systemic steroids, and immunosuppressants in the previous month. 2. Patients with C1 esterase inhibitor deficiency, lymphocytopenia, thrombocytopenia, severe diseases involving heart, liver, or kidney, metabolic disease, or autoimmune disease.

Gender Eligibility: All

Minimum Age: 0 Years

Maximum Age: 18 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • China Medical University Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Jiu-Yao Wang, MD, 886422052121, aim.cmuh@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.